JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thijssen, H. H.
Right arrow Articles by Janssen, Y. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thijssen, H. H.
Right arrow Articles by Janssen, Y. P.

Target-based warfarin pharmacokinetics in the rat: the link with the anticoagulant effect

HH Thijssen and YP Janssen

Department of Pharmacology, University of Limburg, Maastricht, The Netherlands.

Warfarin and congeners bind tightly to the target enzyme vitamin K epoxide reductase. In this study the impact of the target binding on the warfarin pharmacokinetics in plasma and liver of the rat was estimated. Furthermore, the effect of warfarin pharmacokinetics on the time course of inhibition of vitamin K epoxide reductase was followed to find a link with the effect in time on the vitamin K-dependent clotting factor synthesis. Biochemical parameters, drug tissue levels and plasma coagulation activity prothrombin time were followed in normal and phenobarbitone (PB)-treated rats for 12 days after a single dose of S-warfarin (0.5 mg/kg). Warfarin accumulated to saturation (40- 50 pmol/mg of protein) in liver microsomes to remain prolongedly bound and the half-life of elimination exceeded 7 days. PB-treated rats were not found to differ in this respect. In parallel with the steady increase of microsomal-free warfarin binding sites the ex vivo vitamin K epoxide reductase activity recovered, from 10% control activity at t = 3 hr to 70% at t = 12 days. PB-treated rats showed a 1.8-fold higher recovery rate in free enzyme. Blood coagulation was affected during the time in which the ex vivo vitamin K epoxide reductase activity was less than 20% of normal activity. The ex vivo reductase inhibition showed a sigmoidal effect relationship for plasma S-warfarin. Emax appeared to be significantly less than 100% (95% confidence intervals; 83- 91%).(ABSTRACT TRUNCATED AT 250 WORDS)

Volume 270, Issue 2, pp. 554-558, 08/01/1994
Copyright © 1994 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 GeneticsHome page
M. H. Kohn, H.-J. Pelz, and R. K. Wayne
Locus-Specific Genetic Differentiation at Rw Among Warfarin-Resistant Rat (Rattus norvegicus) Populations
Genetics, July 1, 2003; 164(3): 1055 - 1070.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Katashima, K. Yamamoto, Y. Tokuma, T. Hata, Y. Sawada, and T. Iga
Pharmacokinetic and Pharmacodynamic Study of a New Nonsteroidal 5alpha -Reductase Inhibitor, 4-[3-[3-[Bis(4-Isobutylphenyl)Methylamino]Benzoyl]-1H-Indol-1-yl]-Butyric Acid, in Rats
J. Pharmacol. Exp. Ther., March 1, 1998; 284(3): 914 - 920.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
M. Katashima, K. Yamamoto, K. Haraguchi, Y. Tokuma, T. Hata, Y. Sawada, and T. Iga
Tissue Distribution Kinetics of a New Nonsteroidal 5alpha -Reductase Inhibitor, 4-[3-[3-[Bis(4-isobutylphenyl)methylamino]benzoyl]-1H-indol1-yl]-butyric Acid, in Rats
Drug Metab. Dispos., September 1, 1997; 25(9): 1051 - 1058.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1994 by the American Society for Pharmacology and Experimental Therapeutics.